ArticleAIDS patient care and STDs2021
A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.
Abstract read
In one paragraph
Article in AIDS patient care and STDs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Preferences for Long-Acting HIV Pre-Exposure Prophylaxis among Women of Reproductive Age in Low- and Middle-income Countries: A Systematic Review.AIDS and behavior · 2025Pooled it
- Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition.Journal of the International AIDS Society · 2023Pooled it
- Ageing with HIV: Medicine Optimisation Challenges and Support Needs for Older People Living with HIV: A Systematic Review.Drugs & aging · 2023Pooled it
- Accelerating Low-Barrier Use of Long-Acting Antiretroviral Therapy to Maximize Impact in People with HIV and Viremia or Adherence Challenges.Current HIV/AIDS reports · 2026Review
- Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years.JAMA network open · 2026Article
- Optimizing the patient journey: Insights from early implementation of long-acting cabotegravir and rilpivirine in four urban Ryan White-funded clinics in the United States.Journal of the International AIDS Society · 2026Article
- Who could benefit the most from long-acting antiretroviral therapy? perspectives of HIV care providers and people with HIV in Florida.AIDS care · 2025Article
- Willingness to Take Long-Acting Injectable Preexposure Prophylaxis (PrEP) and Preference for PrEP Modalities Among People Who Inject Drugs in Washington, DC.Open forum infectious diseases · 2025Article
- Brief Report: What Matters Most for Long-Acting Antiretroviral Therapy? A Best-Worst Scaling Discrete Choice Experiment.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Article
- Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South.AIDS research and human retroviruses · 2024Article
- "This Is Actually a Really Unique Moment in Time": Navigating Long-Acting HIV Treatment and HIV Cure Research with Analytical Treatment Interruptions-A Qualitative Interview Study in the United States.AIDS research and human retroviruses · 2024Article
- Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States.AIDS and behavior · 2024Article
- Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.AIDS patient care and STDs · 2024Article
- Patient Education and Decision Support for Long-Acting Injectable HIV Antiretroviral Therapy: Protocol for Tool Development and Pilot Testing with Ryan White HIV/AIDS Program Medical Case Management Programs in New York.JMIR research protocols · 2024Article
- A Qualitative Exploration of PrEP Interests, Barriers, and Interventions Among Black and Latina Cisgender Women in the U.S.Archives of sexual behavior · 2024Article
- "What Is the Benefit?": Perceptions and Preferences for Long-Acting Injectable Antiretroviral Therapy Among People Living With HIV.AIDS education and prevention : official publication of the International Society for AIDS Education · 2023Article
- Integrating long-acting injectable treatment to improve medication adherence among persons living with HIV and opioid use disorder: study protocol.Addiction science & clinical practice · 2023Article
- The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch.Current HIV/AIDS reports · 2023Review
- Receipt of Injectable HIV Treatment in Clinic Versus at Home: Perspectives of Persons Living with HIV Infection.AIDS patient care and STDs · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Morgan M PhilbinDepartment of Sociomedical Sciences, Columbia University Mailman School of Public Health, New York, New York, USA.
Carrigan ParishDepartment of Sociomedical Sciences, Columbia University Mailman School of Public Health, New York, New York, USA.
Sadie BergenDepartment of Sociomedical Sciences, Columbia University Mailman School of Public Health, New York, New York, USA.
Deanna KerriganDepartment of Prevention and Community Health, Milken Institute School of Public Health at George Washington University, District of Columbia, USA.
Elizabeth N KinnardDivision of Epidemiology, UC Berkeley School of Public Health, Berkeley, California, USA.
Sarah E ReedTeachers College, Columbia University, New York, New York, USA.
Mardge H CohenDepartment of Medicine, John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, USA.
Oluwakemi SosanyaDepartment of Medicine, Montefiore Medical Center, Bronx, New York, USA.
Anandi N ShethDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Adaora A AdimoraDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Jennifer CocohobaDepartment of Clinical Pharmacy, University of California at San Francisco School of Pharmacy, San Francisco, California, USA.
Lakshmi GoparajuDepartment of Medicine, Georgetown University Medical Center, Washington, District of Columbia, USA.
Elizabeth T GolubDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Margaret FischlDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
Maria L AlcaideDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
Lisa R MetschDepartment of Sociomedical Sciences, Columbia University Mailman School of Public Health, New York, New York, USA.
Funding
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MSF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3MSex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8MSex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2MMACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146241 · NHLBI · EMORY UNIVERSITY · PI Cecile Delille Lahiri, Anandi Nayan Sheth · 2019 to 2026
$24.2MSurviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studiesU01HL146205 · NHLBI · GEORGETOWN UNIVERSITY · PI SEBLE G KASSAYE, DANIEL J MERENSTEIN · 2019 to 2026
$23.5MMWCCS: The Chicago Cook County Clinical Research SiteU01HL146245 · NHLBI · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI Audrey French, Ryan Dee Ross · 2019 to 2026
$23.3MUNC MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146194 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael Bradley Drummond, Michelle Floris-Moore · 2019 to 2026
$23.2MMiami MACS-WIHS Combined Cohort Study Clinical Research SiteU01HL146203 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MARIA LUISA ALCAIDE, Deborah Lynne Jones · 2019 to 2026
$21.2MDevelopment CoreP2CHD058486 · NICHD · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Jennifer S Hirsch, Julien O Teitler · 2014 to 2026
$4.3MGSH Training GrantT32HD049339 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jennifer S Hirsch · 2006 to 2026
$3.4MNCATS NIH HHS UL1 TR000004NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NIAID NIH HHS P30 AI050410NICHD NIH HHS P2C HD058486NICHD NIH HHS T32 HD049339NIDA NIH HHS K01 DA039804
Abstract
Medications for antiretroviral therapy (ART) and preexposure prophylaxis (PrEP) are currently daily pill regimens, which pose barriers to long-term adherence. Long-acting injectable (LAI) modalities have been developed for ART and PrEP, but minimal LAI-focused research has occurred among women. Thus, little is known about how women's history of injection for medical or nonmedical purposes may influence their interest in LAI. We conducted 89 in-depth interviews at 6 sites (New York, NY; Chicago, IL; San Francisco, CA; Atlanta, GA; Chapel Hill, NC; Washington, DC) of the Women's Interagency HIV study. Interviews occurred with women living with HIV (
Indexed as
AdultAgedAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveChildCitiesFemaleHIV InfectionsHumansInjectionsInterviews as TopicMiddle AgedPatient Acceptance of Health CarePre-Exposure ProphylaxisQualitative ResearchUnited StatesAnti-HIV Agentsantiretroviral therapyHIVlong-acting injectablewomen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.